Lifyorli Kit
Product Images NDC 76346-550

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Lifyorli (NDC 76346-550). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Corcept Therapeutics Incorporated, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure Of Relacorilant (Rel04 0002 01)

FDA Label Image

Figure 1 (Rel04 0002 02)

FDA Label Image

Figure 2 (Rel04 0002 03)

FDA Label Image

Principal Display Panel (Rel04 0002 04)

FDA Label Image

Principal Display Panel (Rel04 0002 05)

This text appears to be a description of a medication product called "Reony o Lifyorli" in capsule form with a dosage of 125 mg. The instructions mention taking both a 100 mg capsule and a 25 mg capsule on the same day with food, and also before and after an infusion. It emphasizes swallowing the capsules whole and not altering them. The product seems to come in a package containing three doses.*

FDA Label Image

Principal Display Panel (Rel04 0002 06)

FDA Label Image

Principal Display Panel (Rel04 0002 07)

FDA Label Image

Principal Display Panel (Rel04 0002 08)

This text contains information about a medication in capsule form, with instructions for taking two capsules on the day before, on the day of, and on the day after. It also mentions the NDC number, dosage, and storage recommendations. The medication is available in 3-dose supply blister card packaging, with a mixture of 100 mg and 25 mg capsules. It is advised to store the capsules within a specific temperature range and to keep them out of reach of children. The text suggests referring to the accompanying Patient Information for further details.*

FDA Label Image

Principal Display Panel (Rel04 0002 09)

The text seems to be a description of medication capsules with dosing instructions. The capsules come in blister cards with a total of three capsules: one 100 mg and two 25 mg each. The dosage is one 100 mg capsule and two 25 mg capsules. The medication is identified as NDC: 76346-450-01, and it is indicated for Rx only.*

FDA Label Image

Principal Display Panel (Rel04 0002 10)

This is a description of medication information for Lifyorli capsules. The dosage is a combination of one 100 mg capsule and two 25 mg capsules taken at the same time each day with food. The text also mentions specific instructions such as taking it once a day before, the day of, and the day after an infusion. It emphasizes swallowing the capsules whole and not crushing, chewing, dissolving, or spitting them out. Additionally, it provides storage instructions at a temperature range of 20°C to 25°C.*

FDA Label Image

Principal Display Panel (Rel04 0002 11)

FDA Label Image

Principal Display Panel (Rel04 0002 12)

FDA Label Image

Principal Display Panel (Rel04 0002 13)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.